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Introduction
Pharmaceutical research and development (R&D) historically neglected the infectious diseases
that mainly or exclusively affect poor communities in low- and middle-income countries
(LMICs) [1]. Recently, collaborative clinical research addressing the health needs of LMICs has
becomemore frequent [2], including therapeutic and diagnostic trials for neglected tropical
diseases (NTDs), and is often conducted by noncommercial groups. Clinical trials should com-
ply with sound scientific, ethical, and methodological standards, as expressed in a number of
international codes [3–5]. The GoodClinical Practices (GCP) codes of theWorld Health Orga-
nization (WHO) and of the International Conference of Harmonization (ICH) provide glob-
ally applicable standards for designing, conducting, recording, and reporting clinical trials [4,
5]. Even if primarily meant for the development of newmedicines, they are applicable to other
clinical investigations with an impact on human safety and well-being [5] and to biomedical
research in general [4]. The GoodClinical Laboratory Practices (GCLP) code of the United
Nations Development Programme–World Bank–WHO Special Programme for Research and
Training in Tropical Diseases (TDR) (2009), adapted from the 2003 GCLP Guidelines of the
British Association for Research Quality Assurance (BARQA), provides a GCP-compliant
framework for analysis of biological samples [6]. Compliance with GCP provides public assur-
ance that trial participants are protected and data are credible, whereas compliance with GCLP
specifically ensures the reliability and integrity of laboratory data.
Compliance with these international codesmay seem a daunting task for small, noncom-
mercial research units working in the NTD domain in LMICs, especially when they assume the
role of “sponsor,” i.e., the custodian of compliance with legal and ethical frameworks [7]. The
challenges of implementing GC(L)P in LMICs have been described by different groups in sub-
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Saharan Africa, for instance in the fields of a multi-countrymalaria trial [8] and of vaccine
research, respectively [9]. More recently, they have been discussed in the frame of the Ebola
outbreak inWest Africa [10]. These challenges include, amongst others, (i) contextual con-
straints (e.g., geographical accessibility, electricity supply, Internet connection, distance from
quality suppliers), (ii) the unavailability of research-friendly clinical and laboratory facilities,
(iii) the lack of qualified staff (with research and medical experts being reluctant to relocate to
remote locations), (iv) the vulnerability of communities, (v) the challenge to ensure post-trial
availability and affordability of the research findings, and sometimes (vi) political instability
and insecurity. However, these challenges should neither preclude conducting clinical research
in NTDs nor lead to lowering the GC(L)P standards.
In this PLOS collection,we share the experience of clinical research on NTD-related syn-
dromes conducted by the NIDIAG consortium (http://www.nidiag.org/) between 2010 and
2015 in Cambodia, the Democratic Republic of Congo, Indonesia, Ivory Coast,Mali, Nepal,
and Sudan (ClinTrials.gov identifiers: NCT01589289, NCT01766830, and NCT02105714).
This viewpoint article summarizes the main lessons learnt when implementing GC(L)P in
NTD clinical research.
GC(L)P implementation
Because of the features of NTD-endemic areas, implementing GC(L)P requires a significant
investment in research capacity. The plans for upgrade of local clinical and laboratory facilities
and for staff training should be developed based on thorough pre-study site assessments con-
ducted by clinical, laboratory, and GCP-experts. These visits can often only take place after
approval of the research grant and disbursement of the initial budget. In this case, “reasonable
flexibility”mechanisms should be negotiated with the funder to allow further adaptation of
specific budget lines to local needs [7]. In particular, the local laboratories are often research
naïve, so adequate resources should be secured for their upgrade and supervision.
The training plan should carefully consider the knowledge and skills required for different
roles. Long-term individual training itineraries, including master and PhD programs, are gen-
erally desirable for key staff, e.g., principal investigators and laboratory coordinators from sites
in the South. For co-investigators, nurses, laboratory technicians, community workers, etc., ad
hoc training modules should be offered on-site. These modules should include comprehensive
information on the protocol and overarching research plan to enable everymember of the staff
(whatever his/her role and hierarchical level) to get an adequate understanding of the impor-
tance of their own role and to overcome the sense of disconnect that may be present between
medical and nonmedical personnel. The training on protocol, research ethics, and GC(L)P
should ideally take place at the trial’s initiation, with the trainer(s) remaining on-site during
the first days of recruitment to supervise the team and help them translate procedures into
practices [11]. Training should be a continuous process, allowing the maintenance of teams’
capabilities and motivation throughout the trial. This is especially relevant for remote sites,
where staff retention is problematic and leads to high turnover. The frequency and intensity of
supervision/retrainingvisits should be tailored to the research complexity and risk, and to the
sites’ specific needs.
GCP explicitly require that the quality of the trial be monitored by a qualified person who
oversees the trial’s progress to ensure compliance with the protocol, GCP, ethical, and regula-
tory requirements [4,5]. But, particularly in NTD research, monitoring can have a broader
scope, and site visits also provide opportunities for training and mentoring/coaching by exter-
nal medical and laboratory experts. The latter will play a crucial role in ensuring the quality of
data, because a major challenge for research in NTD settings is represented by the upgrade of
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local laboratories as well as by the harmonization of laboratory quality management systems
across sites and countries. The upgrade of local laboratories will include, among others, the
improvement of infrastructures; the training of the staff; the setup of an adequate, GCLP-com-
pliant quality management system, including participation to external quality assessment (pro-
ficiency testing) [12]; the implementation of measures to mitigate the consequences of extreme
climatic conditions [13]; and the setup or improvement of appropriate procedures for bio-
safety, waste management, etc.
Complementarymeasures to classical monitoring, such as a risk-adapted approach (http://
www.adamon.de/ADAMON_EN/Projectdescription.aspx),may help to keep adequate quality
standards, especially when budget constraints limit external visits, but also in other circum-
stances, e.g., in politically unstable settings where travels may periodically entail security prob-
lems. In internal monitoring [14], in particular, a trainedmember of the team regularly
double-checks a subset of data and performs quality checks on consent forms, protocol, and
standard operating procedures (SOPs)-compliance. This allows early detection of major or sys-
tematic errors. To be valid, internal monitoring should be described in the protocol or SOPs,
conducted according to a predefined plan and in consultation with the external monitor, and
formally documented.Given the limited psychological independence vis-à-vis the study team,
avoiding direct reporting to a more senior member of the study team is suggested. For instance,
in the NIDIAG study, the internal monitor (called “quality manager”) reported directly to the
sponsor.
Clinical data management capacity is often limited or absent at the local research sites in the
domain of NTD. North–South collaborative research provides the opportunity for capacity
building in this field. Sufficient resources should be secured not only for hiring and training
local data entry staff but also for hiring and coaching local data managers, whomay later take
in charge the full data management cycle, i.e., from database development to database cleaning
and lock.
Trial SOPs should ideally be written in collaboration with the future users. They should be
easy to read, practical, and focus on the working instructions and safety. Pretesting in the field
is recommended and should involve all the future users, irrespective of their hierarchical level.
When possible, job aides should also be developed and pretested to provide a pictorial repre-
sentation of any trial-specificprocedure, such as performance of rapid tests.
Protecting communities
NTDs mostly affect socially vulnerable populations served by fragile health systems. Social vul-
nerability [15] has several ethical implications. Wherever access to health care is compromised,
the possibility to get access to free care and reimbursements within a trial becomes, in practice,
an inducement to participation. Poor households will focus on securing otherwise unavailable
health and non-health resources and will underestimate the research-related risks, so becoming
vulnerable to exploitation [16].
Protective measures against exploitation should be in place. This requires a solid risk–bene-
fit assessment; the choice—in collaboration with local Ethics Committees—of fair reimburse-
ment schemes and incentives; the early engagement of key local partners, including the use of
community meetings to inform and get feedback; and the use of adapted consent tools [17].
Participants should receive adequate medical care, and referral should be facilitated if medical
conditions not related to the targeted NTD are diagnosed during the study.
Special attention should be given to local cultural specificities [18]. For instance, in some
contexts, the presence of an independent witness at the consent interview is perceived by illiter-
ate patients as a breach of confidentiality rather than a protection mechanism.More broadly,
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the standard informed consent process is complicated in NTD-endemic contexts by the low lit-
eracy rates and by the difficulty of translating research concepts such as randomization into
local languages (especially when they do not exist in standardized written forms) [19]. A recent
review also confirms that patients in these contexts are less likely to understand the voluntary
nature of participation and the freedom to withdraw [20]. New ways to conduct the informed
consent process, for instance those relying on the support of audiovisuals and multimedia tools
[17], should be investigated on a context-by-context basis to ensure that the consent interview
actually empowers research participants rather than being just the fulfillment of a procedural
requirement.
Research consortia should also consider what the ethical implications are when trial partici-
pants have better access to health care than nonparticipants. To mitigate this, the clinical site
must dispose of sufficient staff to ensure adequate care to all patients, either included or not
included in the research. But much more should be done by planning broader benefit-sharing
measures at the community level. First, trials should result in long-term upgrade of local diag-
nostic and clinical capacity for the benefit of the health system and populations. Research pre-
paredness and training plans should aim at building capacity, and they should be embedded in
a long-term plan for scientific collaboration among North and South research partners that
extends beyond the limited timeframe of a specific funding period. Second, to facilitate future
access to the interventions developed by research, a comprehensive translation to policy strat-
egy is needed, including prior dialoguewith national and international health authorities and
an explicit “access” plan (e.g., preferential prices, intellectual property rights measures, etc.).
Third, an appropriate framework for sharing data is desirable to allow further analyses and
broader scientific collaborations beyond a specific study or a specific consortium, provided
that substantial challenges are adequately dealt with, e.g., harmonization of data quality, pro-
tection of confidentiality of participants and communities, and fair scientific credit to the
researchers and the countries that originated the data [21].
Last but not least, the research protocols should be submitted to an independent Ethics
Committee both in the country of the sponsor and in the country/countrieswhere the study is
carried out because of their complementary knowledge and competences [15] and to ensure
accountability to the public in both contexts.
Managing research projects
Project management skills are essential in clinical research, but they become vital in remote set-
tings in LMICs. The issue of trial supplies provides a good case to show their importance.
Research in NTDs generally involves countries with a poor regulatory environment, so the pre-
selection of quality suppliers and the setup of secured supply channels for sensitive items such
as concomitant medications and reference diagnostic tests is essential to avoid the risk of poor-
quality products [22]. In multicenter/multi-country research, a coordinated and coherent sup-
ply plan across sites is needed to avoid bias related to variable quality of medicines, tests, and
equipment. The service providers for maintenance of medical and laboratory equipment,
including “simple” items like fridges, should be identified upfront, as well as reliable transport
agents (possibly with backup mechanisms). Upfront communication with local authorities will
ensure a transparent and smooth importation process.
Some contractual negotiations are challenging. For instance, the use and storage of biologi-
cal samples, especially those exported for analysis and/or biobanking, have been identified as a
potential source for liability cases [23]. Long-term storage of biological samples for further
research is of paramount importance in NTDs, but it may entail significant cross-border issues,
such as benefit sharing and data access. Thus, a fair, equitable, and feasible biobank governance
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framework will be needed that ensures a fair balance of risks and benefits among all stakehold-
ers [24] and that is translated in adequate contractual arrangements, e.g., the material transfer
agreements and the data sharing agreements. To do so, research consortia, and especially the
sponsor, should invest in adequate management, legal, and administrative skills just as they do
for developing scientific skills [7]. External funding agencies could support ad hoc training on
such skills for researchers and managers (both technically and administratively) in the South.
Final remarks
Building clinical trials capacity at research-naïve sites and institutions in LMICs is always chal-
lenging, and this is particularly true for NTD research, which has traditionally received less
attention and support compared to other medical fields, such as HIV/AIDS,malaria, and
tuberculosis; however, it is feasible [25]. Based on the experience of the NIDIAG consortium,
we believe that GC(L)P principles and requirements can and should be implemented in NTD
clinical research to ensure protection of patients and communities and to ensure data reliabil-
ity. This can be achieved, despite the tremendous challenges in NTD-endemic areas, provided
that a context-sensitive approach to GC(L)P is adopted, with focus on the needs and priorities
of the population and trial sites. In this PLOS NTDs collection,we share the set of SOPs devel-
oped by the NIDIAG consortium and relate some of the challenges we experienced as case
studies.
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